Ergomed PLC (AIM: ERGO) – Positive financial results and a good start to 2015
Ergomed plc, (AIM: ERGO) is a UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs and has a growing portfolio of co-development partnerships. It operates in over 40 countries.
In July 2014 Ergomed listed on AIM raising £11m at IPO. They acquired PrimeVigilance at IPO for £6m in cash and £3m in shares. PrimeVigilance is a post-marketing pharmacovigilance and medical information business that works with pharmaceutical, generic and biotech companies assisting them in managing the global safety of their pharmaceutical drug products and late stage drug developments. It complements Ergomed’s existing business. Ergomed provides clinical development, trial management and pharmacovigilance services to over 60 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development and drug trials from Phase I…